SCHEMBL10197523

SCHEMBL10197523

Brc1ccc2nc(Nc3ccccc3)cnc2c1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 6/20 0.68
PDGFRA P16234 6/20 0.68
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
ALK Q9UM73 2/20 0.51
NPM1 P06748 1/20 0.51
ADRB2 P07550 1/20 0.48
RHOA P61586 4/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALPG P10696 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ABCB1 P08183 1/20 0.42
ABCC1 P33527 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6213413 0.82 PDGFRB (0.74) PDGFRBPDGFRARAB9ANPC1RHOA
SCHEMBL8610333 0.81 PDGFRB (1.00) PDGFRBPDGFRARAB9ANPC1ALK
SCHEMBL1401437 0.81 PDGFRB (0.68) PDGFRBPDGFRARAB9ANPC1RHOA
SCHEMBL7696743 0.81 PDGFRB (0.59) PDGFRBPDGFRARAB9ANPC1ALK
SCHEMBL7696400 0.80 PDGFRB (0.76) PDGFRBPDGFRARAB9ANPC1RHOA
SCHEMBL7691917 0.79 PDGFRB (0.56) PDGFRBPDGFRARHOAMEN1KMT2A
SCHEMBL780200 0.78 PABPC1 (0.42) PDGFRBPDGFRAMEN1KMT2AKDM4E
SCHEMBL1401415 0.78 PDGFRB (1.00) PDGFRBPDGFRARAB9ANPC1MEN1
SCHEMBL18171881 0.78 PDGFRB (0.61) PDGFRBPDGFRANPC1MEN1KMT2A
SCHEMBL1599044 0.77 PABPC1 (0.44) PDGFRBPDGFRAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT PDGFRB 3777/4885PDGFRA 3456/4885RAB9A 2944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.